Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.

Given as a once-weekly injection under the skin using a pre-filled syringe or pen, marstacimab is also the first haemophilia B treatment that works by targeting a protein in the blood clotting process ...

Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care Clinical guideline Reference number: ...

This guidance has been updated and replaced by NICE guideline NG226. Back to top ...

Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for induction and maintenance treatment of untreated advanced or recurrent endometrial ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Date Update 15 May 2025 Expected publication 11 April 2025 - 02 May 2025 Final draft guidance: 1 ...

01 May 2024 Awaiting development. NICE will be undertaking an managed access review of Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high ...

The meeting will take place via Zoom, a secure web conferencing tool. You will need to join the meeting by 10:00am and it is expected to finish at approximately 3:00pm, although this may be subject to ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...